Other immunology — Revenue
Eli Lilly Other immunology — Revenue decreased by 3.9% to $470.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 44.2%, from $326.00M to $470.00M. Over 4 years (FY 2021 to FY 2025), Other immunology — Revenue shows an upward trend with a 167.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization and market adoption of secondary immunology assets, while a decrease may suggest market saturation or declining demand for these niche therapies.
Detailed definition
This metric represents the total net sales generated from the company's secondary or emerging immunology product portfol...
Peer comparison
Peers often report this as 'Other Specialty Pharma' or 'Emerging Immunology' revenue, which is typically compared against total immunology segment growth to assess portfolio breadth.
lly_segment_other_immunology_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.90M | $4.90M | $3.20M | $4.50M | $4.00M | $3.60M | $20.00M | $22.00M | $5.70M | $11.40M | $999.00M | $229.90M | $257.70M | $306.10M | $339.40M | $326.00M | $408.00M | $460.90M | $489.00M | $470.00M |
| QoQ Change | — | -38.0% | -34.7% | +40.6% | -11.1% | -10.0% | +455.6% | +10.0% | -74.1% | +100.0% | >999% | -77.0% | +12.1% | +18.8% | +10.9% | -3.9% | +25.2% | +13.0% | +6.1% | -3.9% |
| YoY Change | — | — | — | — | -49.4% | -26.5% | +525.0% | +388.9% | +42.5% | +216.7% | >999% | +945.0% | >999% | >999% | -66.0% | +41.8% | +58.3% | +50.6% | +44.1% | +44.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other immunology — revenue?
- Eli Lilly (LLY) reported other immunology — revenue of $470.00M in Q1 2026.
- How has Eli Lilly's other immunology — revenue changed year-over-year?
- Eli Lilly's other immunology — revenue increased by 44.2% year-over-year, from $326.00M to $470.00M.
- What is the long-term trend for Eli Lilly's other immunology — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's other immunology — revenue has grown at a 167.5% compound annual growth rate (CAGR), from $32.90M to $1.68B.
- What does other immunology — revenue mean?
- The total revenue generated from the company's secondary or emerging immunology drug products.